Cell-based therapy is showing potential as a possible treatment for Parkinson's disease.
A research team from Rush University Medical Centre in the US found that a novel cell therapy using retinal pigment epithelial cells, known as Spheramine, proved successful in improving the symptoms of the neurological disorder in a number of patients.
Initial trials of the therapy, which took place over a six-year period and monitored six patients, showed that the stabilisation of symptoms was maintained for a minimum of two years and no serious side effects were noted.
Lead researcher Dr Roy Bakay said: "The results of this study are very encouraging – Spheramine is well tolerated through several years of follow-up and improvement in parkinsonian symptoms is sustained."
These positive results have prompted a phase IIB controlled study to further analyse the implications and restrictions of the treatment.
Please click here for advice to help you find the right type of care.